Europese Unie - Grieks - EMA (European Medicines Agency)

meda ab - zaleplon - Διαταραχές έναρξης ύπνου και συντήρησης - Ψυχοληπτικά - Το zerene ενδείκνυται για τη θεραπεία ασθενών με αϋπνία που αντιμετωπίζουν δυσκολία στον ύπνο. Ενδείκνυται μόνο όταν η διαταραχή είναι σοβαρή, απενεργοποιώντας ή υποβάλλοντας το άτομο σε εξαιρετική δυσφορία.

Europese Unie - Grieks - EMA (European Medicines Agency)

roche registration gmbh - ατεζολιζουμάμπη - carcinoma, transitional cell; carcinoma, non-small-cell lung; urologic neoplasms; breast neoplasms; small cell lung carcinoma - Αντινεοπλασματικοί παράγοντες - urothelial carcinomatecentriq as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (uc):- after prior platinum containing chemotherapy, or - who are considered cisplatin ineligible, and whose tumours have a pd-l1 expression ≥ 5% (see section 5. non-small cell lung cancer tecentriq, in combination with bevacizumab, paclitaxel and carboplatin, is indicated for the first-line treatment of adult patients with metastatic non-squamous non small cell lung cancer (nsclc). in patients with egfr mutant or alk-positive nsclc, tecentriq, in combination with bevacizumab, paclitaxel and carboplatin, is indicated only after failure of appropriate targeted therapies (see section 5. tecentriq, in combination with nab paclitaxel and carboplatin, is indicated for the first line treatment of adult patients with metastatic non-squamous nsclc who do not have egfr mutant or alk positive nsclc (see section 5. tecentriq as monotherapy is indicated for the first-line treatment of adult patients with metastatic non-small cell lung cancer (nsclc) whose tumours have a pd-l1 expression ≥ 50% tumour cells (tc) or ≥ 10% tumour-infiltrating immune cells (ic) and who do not have egfr mutant or alk-positive nsclc (see section 5. tecentriq ως μονοθεραπεία ενδείκνυται για τη θεραπεία ενηλίκων ασθενών με τοπικά προχωρημένο ή μεταστατικό μη μικροκυτταρικό καρκίνο του πνεύμονα, μετά από προηγούμενη χημειοθεραπεία. patients with egfr mutant or alk positive nsclc should also have received targeted therapies before receiving tecentriq (see section 5. small cell lung cancertecentriq, in combination with carboplatin and etoposide, is indicated for the first-line treatment of adult patients with extensive-stage small cell lung cancer (es-sclc) (see section 5. hepatocellular carcinomatecentriq, in combination with bevacizumab, is indicated for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (hcc) who have not received prior systemic therapy (see section 5. urothelial carcinomatecentriq as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (uc):- after prior platinum containing chemotherapy, or- who are considered cisplatin ineligible, and whose tumours have a pd-l1 expression ≥ 5% (see section 5. non-small cell lung cancertecentriq as monotherapy is indicated for the first-line treatment of adult patients with metastatic non-small cell lung cancer (nsclc) whose tumours have a pd-l1 expression ≥ 50% tumour cells (tc) or ≥ 10% tumour-infiltrating immune cells (ic) and who do not have egfr mutant or alk-positive nsclc (see section 5. tecentriq ως μονοθεραπεία ενδείκνυται για τη θεραπεία ενηλίκων ασθενών με τοπικά προχωρημένο ή μεταστατικό μη μικροκυτταρικό καρκίνο του πνεύμονα, μετά από προηγούμενη χημειοθεραπεία. patients with egfr mutant or alk positive nsclc should also have received targeted therapies before receiving tecentriq (see section 5. triple-negative breast cancertecentriq in combination with nab-paclitaxel is indicated for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (tnbc) whose tumours have pd-l1 expression ≥ 1% and who have not received prior chemotherapy for metastatic disease.

Cyprus - Grieks - Φαρμακευτικών Υπηρεσιών του Υπουργείου Υγείας

tillotts pharma gmbh (0000010051) warmbacher str. 80, rheinfelden, 79618 - mesalazine - suppositories - 500mg - mesalazine (0000089576) 0.500000000000g - mesalazine

Cyprus - Grieks - Φαρμακευτικών Υπηρεσιών του Υπουργείου Υγείας

viatris healthcare limited. (0000012172) damastown industrial park, mulhuddart, dublin 15, d15 xd71 - fluvoxamine maleate - film coated tablets - 50mg - fluvoxamine maleate (0061718829) 50mg - fluvoxamine

Cyprus - Grieks - Φαρμακευτικών Υπηρεσιών του Υπουργείου Υγείας

viatris healthcare limited. (0000012172) damastown industrial park, mulhuddart, dublin 15, d15 xd71 - fluvoxamine maleate - film coated tablets - 100mg - fluvoxamine maleate (0061718829) 100mg - fluvoxamine

Cyprus - Grieks - Φαρμακευτικών Υπηρεσιών του Υπουργείου Υγείας

medochemie ltd (0000003169) 1-10 constantinoupoleos str, lemesos, 3011, 51409 (3505) - carbidopa monohydrate; levodopa - tablets - 100mg/10mg - carbidopa monohydrate (8000001794) 10,8mg; levodopa (0000059927) 100mg - levodopa and decarboxylase inhibitor

Cyprus - Grieks - Φαρμακευτικών Υπηρεσιών του Υπουργείου Υγείας

medochemie ltd (0000003169) 1-10 constantinoupoleos str, lemesos, 3011, 51409 (3505) - levodopa; carbidopa monohydrate - tablets - 250mg/25mg - levodopa (0000059927) 250mg; carbidopa monohydrate (8000001794) 27mg - levodopa and decarboxylase inhibitor

Cyprus - Grieks - Φαρμακευτικών Υπηρεσιών του Υπουργείου Υγείας

medochemie ltd (0000003169) 1-10 constantinoupoleos str, lemesos, 3011, 51409 (3505) - carbidopa monohydrate; levodopa - tablets - 100mg/25mg - carbidopa monohydrate (8000001794) 27mg; levodopa (0000059927) 100mg - levodopa and decarboxylase inhibitor

Cyprus - Grieks - Φαρμακευτικών Υπηρεσιών του Υπουργείου Υγείας

codal-synto limited (0000010484) 21 constantinoupoleos str., limassol, 3011, 51785 (3508) - levodopa; carbidopa monohydrate - tablets - 250/25mg - levodopa (0000059927) 250mg; carbidopa monohydrate (8000001794) 27mg - levodopa and decarboxylase inhibitor

Cyprus - Grieks - Φαρμακευτικών Υπηρεσιών του Υπουργείου Υγείας

codal-synto limited (0000010484) 21 constantinoupoleos str., limassol, 3011, 51785 (3508) - levodopa; carbidopa monohydrate - tablets - 100/10mg - levodopa (0000059927) 100mg; carbidopa monohydrate (8000001794) 10,8mg - levodopa and decarboxylase inhibitor